Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as INS365 Ophthalmic Solution
INS365 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INS365 Ophthalmic Solution | DRUG | - |
Inclusion Criteria: * have Non-Sjogren's associated dry eye disease with symptoms lasting greater than 6 months * had intermittent or regular artificial tear use within past 3 months Exclusion Criteria: * had LASIK surgery * had punctal occlusion or cauterization within last 3 months
INS365 is being developed for keratoconjunctivitis sicca, commonly known as dry eye disease. It is an ophthalmic solution studied in patients with this condition. The program is in Phase 3 clinical development, and the drug has not been approved by the FDA.
INS365 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company is the sponsor of the clinical program evaluating INS365 ophthalmic solution in patients with keratoconjunctivitis sicca.
INS365 is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The drug remains investigational and has not been approved by the FDA for any indication.
INS365 has been studied in one Phase 3 trial, NCT00037661, titled Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye. The trial enrolled 222 patients with keratoconjunctivitis sicca, was randomized and double blind, and has been completed.
Yes. INS365 Ophthalmic Solution is the same asset as INS365, referring to the ophthalmic formulation of the drug. Both names describe the small molecule being developed by Merck & Company, Inc. for keratoconjunctivitis sicca.